Gilead Sciences' SWOT analysis: HIV leader faces oncology hurdles, seeks liver disease growth
|
HIV
Franchise Remains Core Strength. Gilead's HIV business continues to be
the cornerstone of its success. The company's flagship drug,
Biktarvy, ... |